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Abstract: Tetraspanin transmembrane proteins
have a metastasis suppressor effect by acting as cell
motility brakes in tumor cells. CD53 is a panleuko-
cyte antigen that belongs to the tetra-span superfam-
ily. Human neutrophils express high levels of CD53.
We tested the hypothesis that this antigen level
changes when cells are activated. Treatment of
human neutrophils with their physiological activa-
tors, tumor necrosis factor a or platelet-activating
factor, resulted in down-regulation of this antigen
from the cell surface, as assessed by immunofluores-
cence flow cytometry. Similar responses were ob-
served when neutrophils were stimulated with che-
motactic N-formyl-methionyl-leucyl-phenylalanine,
phorbol ester, or the calcium ionophore ionomy-
cin. The CD53 antigen down-regulation upon neu-
trophil stimulation was further confirmed by immu-
noblotting analysis and was not correlated with a
change in the level of CD53 transcripts. This CD53
antigen down-regulation paralleled that of CD43
and CD44 antigens in these cells, despite their
different protein structure. The down-regulation of
the three antigens CD53, CD43, and CD44 could
be inhibited by phenylmethylsulfonyl fluoride, sug-
gesting that CD53 antigen down-regulation is the
result of the activation of a proteolytic mechanism.
Down-regulation of CD53 antigen level, as a result
of cellular stimulation, might play a role in the
different aspects of neutrophil biology, by modulat-
ing its interactions on the cell surface. J. Leukoc.
Biol. 63: 699–706; 1998.
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INTRODUCTION
The tetraspanin family is a novel group of membrane proteins
that has been implicated in several important biological
processes, but their physiological role in cell biology is not yet
known [1–3]. Therefore, this protein family is still defined by
the common structural features of its members [3]. They have
four transmembrane domains, their amino and carboxy ends are
facing the cytoplasm, and have two, small and large, extracellu-
lar loops. The large extracellular loop accounts for most of the
differences found among the distinct members of this group, it
is glycosylated in most cases and appears to be implicated in
binding to an unknown ligand [3]. Tetra-span transmembrane
proteins include several tumor markers as well as positive and
negative regulators of cell proliferation and of cell motility.
Among the tetra-span transmembrane proteins [2, 3] are CD37,
a B cell marker; CD53/OX44, which modulates growth proper-
ties; CD81/TAPA1, which has antiproliferative properties;
CD63/ME491, a melanoma antigen; CD9/MRP1, which affects
cell motility; and CD82/IA4/C33/KAI1, which inhibits synci-
tium formation in HTLV-I-infected cells [4].
Some tetra-span transmembrane proteins, such as CD9/
MRP1 and CD82/KAI1, have been shown to exert a metastasis
suppressor phenotype in pancreatic and prostate cancer [5, 6].
This phenotype appears to be the result of a braking effect on
cell motility, thus low levels will facilitate cell motility and
result in an increased capacity to form metastasis. In five types
of cancer, melanoma [7], non small-cell lung cancer [8, 9],
breast [10], prostate [11], and pancreas [12], the level of
tetra-span antigens supports the correlation of low level expres-
sion with poor prognosis.
Several tetraspanin antigens are known to promote cellular
adhesion. This has been demonstrated for CD81 [13], CD9 [14],
and CD53 [15, 16]. These three antigens are also known to
coprecipitate together, suggesting they are forming a complex
on the cell membrane which is physically associated with
integrins on the cell surface and modulates their biological
functions [17–19].
We reasoned that the braking action is a phenotypic manifes-
tation of the biological effect of tetra-span proteins, which can
modulate integrin function [17–19]. In normal cells where
migration plays an important role, such as neutrophil response
to infection, which requires mobilization of cells to the site of
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local infection, these proteins could modulate their levels depending
on the activation state. Thus, it could be envisaged that when cells
are stimulated with chemotactic agents there should be a reduction
in the cell surface level of tetraspanin proteins. We tested this
hypothesis using human neutrophils and determining the changes of
CD53 antigen levels in response to different types of stimuli.
The human CD53 antigen [3] is a tetraspanin panleukocyte
antigen that is detected in cells of lymphoid and myeloid
lineages, including B and T lymphocytes, macrophages, neutro-
phils, and natural killer (NK) cells, but not in erythroid cells [1,
2]. CD53 has been associated with immunocompetence and
positive selection in the thymus [20, 21]. CD53 is not present in
cell lineages from other origins, differing in this regard from
other tetraspanin proteins that are also present in cells with an
epithelial origin, including several types of carcinoma [3]. The
widespread distribution of CD53 in all leukocytes suggests that
it might have a similar biological role in all of them. CD53
cross-linking, in rat macrophages, activates a cellular response
that is mediated by protein kinase C (PKC) and releases nitric
oxide as a consequence of inducing expression of nitric oxide
synthase [22].
Neutrophil biology requires the participation of several types
of membrane proteins to carry out different functions, like
attachment and detachment to endothelium and target cells as
well as cellular migration to places of local infection. These
processes require selective and regulated neutrophil-endothe-
lium and cell-cell interactions, which are mediated by a large
array of membrane proteins, as well as regulation of cell
motility [23–25]. Neutrophil activation in response to different
signals, such as chemotactic peptides or cytokines, involves the
modulation of the cell surface expression of several proteins,
some are down-regulated and others are up-regulated. This
change in the levels of cell surface proteins results in neutro-
phil detachment, migration, rolling, extravasation, and accumu-
lation at the site of injury [25–29]. In this context, proteolytic
modulation of membrane proteins is becoming an important
regulatory mechanism in cell biology. This proteolytic down-
regulation has been shown on an increasing number of proteins,
including some cytokine receptors such as tumor necrosis
factor a (TNF-a) receptor and interleukin-6 (IL-6) receptor
[30], Fas ligand [31], adhesion molecules such as L-selectin
[32, 33], ICAM-3 [34], CD43, and CD44 [35]. Specific
proteases are present on the cell surface to specifically activate
the thrombin and plasminogen systems [36, 37]. Cell surface
proteolytic activity has also been implicated in human neutro-
phil activation [38, 39].
We have found that the cell surface expression of the CD53
antigen is down-regulated on neutrophil activation. This anti-
gen down-regulation is triggered by several physiological
neutrophil activating agents, and correlates well with the
previously reported proteolytic down-regulation of other glyco-
proteins, CD43 and CD44 [35].
MATERIALS AND METHODS
Chemicals and reagents
Cell culture reagents were from Flow Laboratories (Irvine, CA). Phorbol
12-myristate 13-acetate (PMA), fMLP, cytochalasin B, phenylmethylsulfonyl
fluoride (PMSF), diisopropyl fluorophosphate (DIFP), Bdellin, and antitrypsin
inhibitor were from Sigma (St. Louis, MO). Ficoll-Hypaque was from Pharmacia
(Uppsala, Sweden). Ionomycin was from Calbiochem (San Diego, CA). Acrylam-
ide, bisacrylamide, ammonium persulfate, TEMED, and prestained molecular
weight markers were from Bio-Rad (Hercules, CA). All other chemicals were
from Merck (Darmstadt, Germany) or Sigma.
Monoclonal antibodies
mAb were used as hybridoma culture supernatants. MEM53 (anti-human
CD53) was a gift of Dr. Vaclav Horejsi (Czech Academy of Sciences, Prague,
Czech Republic) and was also obtained from Serotec (Oxford, UK). The mAb
Bear-1, recognizing CD11b, was kindly provided by Dr. J. E. De Vries (Unicet,
Lyon, France) [40]. Anti-CD43 (mAb TP1/36.1), anti-CD44 (mAb HP2/9), and
mAb W6/32 (specific for a monomorphic determinant on HLA-A,B molecules)
[35, 41] were kindly provided by Dr. F. Sa´nchez-Madrid (Hospital de La
Princesa, Madrid, Spain). P3X63 myeloma culture supernatant was used as
negative control.
Neutrophil isolation
Human neutrophils were obtained from fresh peripheral blood by dextran
sedimentation and centrifugation on Ficoll-Hypaque followed by hypotonic
lysis of residual erythrocytes as previously described [42]. The final cell
preparation contained more than 98% neutrophils, as assessed by Giemsa-
Wright staining.
Immunofluorescence flow cytometry
Immunofluorescence flow cytometry analysis was performed in a FACStar-Plus
flow cytometer (Becton-Dickinson, San Jose, CA) as previously described [43].
Cells were incubated at 4°C with the corresponding mAb followed by washing
and labeling with a fluorescein isothiocyanate (FITC)-labeled-goat anti-mouse
IgG antibody (DAKO, Glostrup, Denmark). Linear and logarithmic immunoflu-
orescence values were obtained in each experiment and the fluorescence
produced by the myeloma P3X63 supernatant was considered as background.
Specific linear fluorescence was obtained by subtracting the control fluores-
cence in which the mAb was substituted by the myeloma P3X63.
Neutrophil activation
Cells were resuspended at 3 3 106 neutrophils/mL in N-2-hydroxyethylpipera-
zine-N8-2-ethanesulfonic acid (HEPES)/glucose buffer (150 mM NaCl, 5 mM
KCl, 10 mM HEPES, 1.2 mM MgCl2, 1.3 mM CaCl2, 5.5 mM glucose, pH 7.5)
and incubated in the absence or presence of distinct stimuli at 37°C for the
times indicated in the respective legends. Subsequently, cells were sedimented
by centrifugation at 300 g for 10 min. Supernatants were saved and lyophilized
to determine release of proteins, and the pelleted cells were saved to determine
the content of different cell surface antigens by flow cytometry. Also,
sedimented cells were used to obtain membranes for immunoblot analysis.
Cells were disrupted by freeze-thaw, and membranes were sedimented by
centrifugation at 100,000 g for 90 min at 4°C in a Beckman TLA rotor [44].
Membrane pellets were resuspended in 50 mM Tris-HCl, pH 7.5, containing 2
mM PMSF and stored at 220°C until use.
Immunoblot analysis
Total membrane proteins (40 µg) from resting and activated human neutrophils
were separated through sodium dodecyl sulfate (SDS), 10 or 15% polyacryl-
amide gel electrophoresis under reducing conditions, in the presence of
2-mercaptoethanol, transferred to nitrocellulose filters, and subjected to
immunological detection as previously described [45]. After electroblotting and
blocking for 1–2 h in 2% (w/v) powdered defatted milk in TBS (50 mM
Tris-HCl, pH 8.0, 150 mM NaCl), the nitrocellulose filters were incubated
overnight with the specific anti-CD53 mAb at a dilution of 1/400 in TBS buffer
containing 0.05% (v/v) Tween 20. Signal was developed using the biotin-
streptavidin-horseradish peroxidase system and detected with the ECL kit
(Amersham, Little Chalfont, UK) according to the manufacturer’s instructions.
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Northern blot analysis
RNA was extracted from the cells according to standard protocols using the
acid guanidinium-phenol-chloroform extraction method. Ten micrograms of
total RNA were electrophoresed on 0.9% agarose-formaldehyde gels and then
transferred to Hybond-N nylon membranes (Amersham) and hybridized to the
appropriate probe following standard protocols [46]. We used the human cDNA
clone, ph15CD53, containing the complete CD53 coding region [P. A. Lazo,
unpublished results] as a probe for CD53. For internal controls a cDNA probe
against glyceraldehyde-3-phosphate dehydrogenase was used.
RESULTS
Human neutrophils are physiologically activated by the cyto-
kine TNF-a and PAF, a potent phospholipid mediator. Both
molecules play important regulatory roles in neutrophil recruit-
ment to sites of injury. We found that CD53 was down-regulated
after neutrophil stimulation with 500 U/mL of TNF-a (Fig. 1).
TNF-a is also known to down-regulate sialophorin (CD43) and
the hyaluronic acid receptor (CD44) during neutrophil activa-
tion by a proteolytic mechanism that is inhibited by PMSF [35].
We determined these two antigens as down-regulation controls
in all experiments. As additional control antigens we used
CD11b, an integrin that is up-regulated in neutrophil activation
[44], and HLA-A,B, which is not affected by cell stimulation.
As shown in Figure 1, CD53 antigen, as well as CD43 and
CD44, were down-regulated, whereas the cell surface expres-
sion of CD11b was up-regulated, and that of HLA-A,B was
unaffected. We conclude from these data that CD53 antigen
down-regulation is also part of the human neutrophil response
to TNF-a (Fig. 1, Table 1). All TNF-a-induced down-
regulation reactions were inhibited by the addition of 2 mM
PMSF. The stimulation of human neutrophils with 1 µM PAF for
15 min also triggered a reduction in CD53, CD43, and CD44
antigen levels, which were partially inhibited by the addition of
PMSF (Table 1). It is interesting to note that PMSF did not
affect the overexpression of CD11b (Table 1), thus ruling out
the possibility that PMSF could block the overall neutrophil
activation mechanism.
Neutrophils can be activated by stimulation with fMLP, a
short chemotactic peptide that induces changes in the cell
surface expression levels of several antigens [47]. fMLP
stimulates neutrophils through a PKC-dependent pathway [48,
49]. We have determined the fate of CD53 antigen in human
neutrophils that have been stimulated with fMLP (Fig. 2, Table
1). The addition of 1 µM fMLP for 15 min induced a reduction
in the cell surface CD53 antigen level on these cells (Fig. 2).
This CD53 down-regulation was also observed after 5 min
incubation with fMLP (data not shown). The fMLP-induced
Fig. 1. Effect of TNF-a on the cell surface antigen expression in human neutrophils. (A) Neutrophils were incubated for 15 min at 37°C in the absence of any
stimulus (solid lines) or in the presence of 500 U/mL TNF-a (dashed lines). (B) Neutrophils were incubated for 15 min with 500 U/mL TNF-a in the presence of 2 mM
PMSF (solid lines). Cells were stained for CD53, CD11b, HLA-A,B, CD43, and CD44 antigens and analyzed by immunofluorescence flow cytometry as described in
Materials and Methods. Staining with negative control antibody P3X63 is also shown (A, dotted line). One representative experiment out of four is shown.
TABLE 1. Effect of Distinct Physiological Stimuli on the Cell-Surface Expression of Several Leukocyte Antigens in Human Neutrophils
Cell surface antigen 37°C TNF-a TNF-a 1 PMSF PAF PAF 1 PMSF fMLP fMLP 1 PMSF
CD53 MEM53 46 6 7 (100) 26 6 4 (56) 41 6 5 (90) 30 6 4 (65) 46 6 2 (100) 19 6 5 (41) 40 6 3 (87)
CD43 sialophorin 87 6 7 (100) 51 6 7 (58) 97 6 9 (111) 56 6 8 (64) 98 6 9 (113) 33 6 6 (38) 86 6 3 (99)
CD44 hyaluronate
receptor 96 6 8 (100) 58 6 8 (60) 102 6 9 (106) 63 6 7 (66) 97 6 8 (101) 31 6 5 (32) 92 6 7 (96)
CD11b Mac1, Mo1 216 6 15 (100) 289 6 13 (133) 301 6 21 (139) 298 6 10 (138) 296 6 12 (137) 396 6 27 (183) 331 6 24 (153)
HLA-A,B 48 6 7 (100) 43 6 2 (90) 45 6 4 (94) 44 6 1 (92) 46 6 4 (96) 41 6 6 (85) 43 6 3 (90)
Neutrophils were incubated for 15 min at 37°C either in the absence or in the presence of the following stimuli: 500 U/mL TNF-a, 1 µM PAF, 1 µM fMLP. When
indicated, cells were preincubated for 5 min with 2 mM PMSF. Cells were analyzed by immunofluorescence flow cytometry. Data are expressed as means 6 SD of
specific linear fluorescence intensity values of four independent experiments. The values in parentheses indicate the percentage of cell surface antigen expression
with respect to that of untreated control cells at 37°C with no additions. The fMLP experiments were carried out in the presence of 5 µg/mL cytochalasin B.
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CD53 down-regulation was blocked by addition of PMSF (Fig.
2; Table 1). The fMLP-induced CD53 down-regulation paral-
leled the responses of CD43 and CD44, used as control
antigens for down-regulation (Table 1). In contrast, CD11b was
up-regulated, and HLA-A,B was not affected (Table 1).
Signaling mediated by PKC, such as stimulation with
phorbol esters or Ca21 [50], can also activate human neutro-
phils. Therefore, we tested the effects of PMA and the Ca21
ionophore, ionomycin, on CD53 surface level. Phorbol esters
and Ca21 ionophores are potent activators of neutrophil func-
tions. Shortly after the addition of 100 ng/mL PMA or 3 µM
ionomycin to neutrophils there was a decrease in the CD53
antigen cell surface level (Fig. 2, Table 2). The PMA-induced
CD53 down-regulation was very rapid, and similar to the
fMLP-induced down-regulation (Fig. 2). Down-regulation could
be detected following PMA treatment as rapidly as 5 min (data
not shown). This mechanism appears to be mediated by PKC
signaling, as preincubation of neutrophils with either 50 µM H7
or 150 nM staurosporine completely abrogated CD53 down-
regulation (data not shown). CD53 (Fig. 3A) responded to PMA
in the same way as CD43 (Fig. 3C) and CD44 (Fig. 3D). The use
of serine protease inhibitors, such as PMSF, prevented the PMA
or ionomycin-induced down-regulation of CD53 cell surface
expression (Fig. 2, Table 2), as well as that of CD43 and CD44
(Fig. 3, Table 2). The control CD11b up-regulation was also
observed in our assays (Fig. 3B), but the increase in this antigen
level was smaller in the presence of PMSF (Table 2). In an
attempt to further characterize the protease implicated in CD53
down-regulation we used additional protease inhibitors. DIFP,
another serine protease inhibitor, prevented CD53 down-
regulation, whereas Bdellin, an inhibitor of metalloproteinases,
leupeptin, and anti-trypsin inhibitor did not prevent CD53
down-regulation (data not shown). Based on these observations,
we suggest that a signal mediated by PKC can proteolytically
down-regulate CD53 antigen.
Time course studies of CD53 down-regulation on PMA or
TNF-a treatment showed that CD53 down-regulation was
almost complete after 1 h incubation (Fig. 4).
The loss of CD53 antigen could be due to internalization by
endocytosis as a consequence of neutrophil stimulation. There-
fore, we performed experiments in the presence of cytochalasin
B, a microfilament disrupting agent, which has been used as an
inhibitor of endocytosis [51]. Cytochalasin B did not prevent
down-regulation of CD53 antigen (Table 2). Cytochalasin B has
been widely used to enhance neutrophil responses, increasing
exocytosis. This is clearly observed in Table 2, where the
up-regulation of CD11b is highly increased as a result of the
mobilization of internal CD11b pools in intracellular granules [44].
Immunoblotting of CD53 antigen from neutrophil mem-
branes clearly showed a diminished surface expression of this
molecule on activated, compared with resting neutrophils (Fig.
5A), in accordance with the immunofluorescence flow cytome-
try data. The human CD53 antigen can be N-glycosylated and
both forms, glycosylated and non-glycosylated, are present on
the cellular membrane of different cell types [52]. In human
Fig. 2. Down-regulation of CD53 antigen on cell stimulation with PMA or
fMLP and its prevention by PMSF in human neutrophils. (A) Neutrophils were
incubated for 15 min at 4°C (solid line) or 37°C (dashed line) in the absence of
any stimulus. (B) Neutrophils were incubated for 15 min at 37°C in the
presence of 100 ng/mL of PMA (solid line) or 1 µM fMLP (dashed line). (C)
Neutrophils were incubated as in (B) but in the presence of 2 mM PMSF during
the activation process. Cells were stained for CD53 antigen and analyzed by
immunofluorescence flow cytometry. Staining with the negative control P3X63
is also shown (A, dotted line). One representative experiment out of five is
shown.
Fig. 3. Effect of PMA on the cell-surface expression of CD53, CD11b, CD43,
and CD44 antigens in human neutrophils. Neutrophils were incubated in the
absence of any stimulus or in the presence of 100 ng/mL PMA for 15 min at
37°C. Resting (solid line) and stimulated (dashed) cells were stained for CD53
(A), CD11b (B), CD43 (C), and CD44 (D) antigens and analyzed by immunoflu-
orescence flow cytometry as described in Materials and Methods. Cells were
also incubated with PMA in the presence of 2 mM PMSF (dotted dashed line)
and examined for the above antigens. Staining with the negative control P3X63
is also shown (A, dotted line). One representative experiment out of four is
shown.
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neutrophils, we detected by immunoblotting two bands of
approximately 35 and 21 kDa, corresponding to both forms of
CD53. Treatment with PMA resulted in the loss of both CD53
forms and the addition of PMSF inhibited this proteolytic
down-regulation. These observations confirmed that glyco-
sylated and non-glycosylated CD53 were down-regulated, likely
by proteolysis. As control antigen in these experiments we used
CD43, which is also lost after stimulation with PMA, and this
response is also inhibited by addition of PMSF (Fig. 5A). The
proteolytic attack could have two effects, either solubilizing the
CD53 antigen or simply destroying the only accessible loop to
the antibody and thus losing immunoreactivity. We were unable
to detect soluble CD53 antigen (data not shown). These results
suggest that the proteolytic attack could affect the extracellular
loop where the antigenic epitope is located.
We also determined whether, as a result of PMA stimulation,
there were changes in the level of mRNA coding for CD53 (Fig.
5B). The drop in CD53 cell surface expression after neutrophil
activation suggested that the synthesis of new antigen might
also be turned off as a result of down-regulation. Total RNA
from neutrophils prepared at different time points before and
after different types of stimulation were analyzed by Northern
blot. The blot was hybridized to a human CD53 cDNA probe.
As shown in Figure 5B, there were no changes in the CD53
mRNA level despite the reduction in membrane antigen levels.
DISCUSSION
Tetraspanin transmembrane proteins in tumor cells appear to
function as metastasis suppressors, by acting as brakes of cell
motility [5, 6]. Thus low levels of these proteins have been
TABLE 2. Effect of PMA and ionomycin on the cell surface expression of several leukocyte antigens in human neutrophils
and inhibition by PMSF
Antigen/CD 4°C 37°C PMA PMA 1 PMSF Ionomycin
Ionomycin 1
PMSF
Ionomycin 1
cytochalasin
B 1 PMA
MEM53 CD53 45 6 5 46 6 7 (100) 16 6 5 (34) 33 6 9 (72) 23 6 5 (51) 38 6 2 (83) 19 6 22 (42)
Sialophorin CD43 91 6 8 87 6 7 (100) 27 6 4 (31) 80 6 9 (91) 20 6 1 (23) 105 6 8 (120) N.D.
Hyaluronate receptor CD44 97 6 9 96 6 8 (100) 40 6 6 (41) 94 6 7 (97) 21 6 3 (21) 87 6 7 (90) N.D.
Mac1, Mo1 CD11b 181 6 11 216 6 15 (100) 481 6 25 (222) 320 6 41 (148) 484 6 31 (224) 301 6 48 (139) 545 6 35 (301)
HLA-A,B 46 6 3 48 6 7 (100) 38 6 6 (83) 42 6 6 (91) 39 6 5 (81) 41 6 4 (90) 47 6 4 (98)
Neutrophils were held at 4°C or treated for 15 min at 37°C either in the absence of any stimulus or in the presence of the following stimuli: 100 ng/mL PMA, 3 µM
ionomycin. When indicated, cells were preincubated for 5 min with 2 mM PMSF or 5 µg/mL cytochalasin B. Cells were analyzed by immunofluorescence flow
cytometry. Data are expressed as means 6 SD of specific linear fluorescence intensity values. Mean values were obtained from four independent cells experiments. In
parentheses are the values represented as percentage of the cell surface antigen expression with respect to that found in untreated control cells determined at 37°C.
N.D., not determined.
Fig. 4. Time-course assay of the effect of PMA and TNF-a on CD53 antigen
surface level in human neutrophils. Neutrophils were incubated at 37°C in the
absence (solid line) or in the presence of 100 ng/mL PMA (A) or 500 U/mL (B)
for 15 min (dashed line with plus signs), 30 min (dotted dashed line), and 60
min (dashed line). Then cells were stained for CD53 antigen and analyzed by
immunofluorescence flow cytometry. Staining with the negative control P3X63
is also shown (dotted line). One representative experiment out of three is shown.
Fig. 5. Western blot and Northern blot analysis of CD53 in resting and
activated human neutrophils. (A) Western blot analysis of membrane fractions
from resting and activated human neutrophils. Blots contained 40 µg of
membrane proteins from control untreated neutrophils, neutrophils treated with
PMA for 30 min, and neutrophils treated for 30 min with PMA in the presence
of PMSF. Blots were analyzed with anti-CD53 mAb (top panel) or with anti
CD43 mAb (bottom panel). (B) Northern blot analysis of mRNA levels of CD53
in human neutrophils after stimulation with PMA, fMLP, or TNF-a for different
incubation times. The Northern blot was hybridized to a human complete cDNA
probe for CD53. Basal control levels in untreated neutrophils are also shown.
Autoradiograph was developed after 24-h exposure.
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correlated with an increased metastatic potential, and thereby
poor prognosis [7–11].
In human neutrophils, as a result of activation, there is an
increase in cell motility in order to migrate to the site of injury.
Therefore we postulated that if the CD53 panleukocyte antigen
was having an inhibitory effect on cell motility in this cell type,
it should reduce its surface level after physiological stimula-
tion.
We herein report a significant down-regulation in the levels
of CD53 antigen on the cell surface during human neutrophil
activation by different activators, such as TNF-a, PAF, and
fMLP, signaling through a receptor-mediated pathway, and
PMA and ionomycin, signaling via PKC, through a non-receptor
route. The regulatory effects of TNF-a and PAF on CD53 cell
expression were weaker than those exerted by PMA or ionomy-
cin. However, on 1-h incubation with either PMA or TNF-a,
CD53 surface antigen expression was almost completely re-
duced (Fig. 4). The differences in the CD53 cell surface levels
between resting and TNF-a-activated neutrophils are similar to
those detected between cells with low and high metastatic
potential [8–12]. This change in the cell surface antigen level
occurred rapidly and and was already detectable after 5 min
stimulation. This rapid response is not accompanied by changes
at the mRNA level. The mechanism of this change in CD53
levels is not the result of internalization by endocytosis, as
shown by the lack of effect of cytochalasin B. The fact that the
protease inhibitor PMSF blocks the down-regulation of CD53,
but not the up-regulation of the cell surface expression of
CD11b induced by TNF-a or PAF may indicate that activation
of a specific protease is the mechanism involved in the
modulation of CD53. Furthermore, DIFP, another serine prote-
ase inhibitor, also prevents CD53 down-regulation. These data
agree with a previous report showing that PMSF prevented the
CD43 and CD44 proteolytic down-regulation with no effect on
CD11b up-regulation when neutrophils were activated with
TNF-a [35]. There is evidence showing that several protease
inhibitors can affect different neutrophil functions [38, 39],
which is consistent with our observation that in the presence of
PMSF the up-regulation of CD11b was smaller when triggered
by non-membrane receptor stimuli (Table 2). Thus, protease
activation could mediate several aspects of neutrophil biology.
The CD53 down-regulation herein reported was similar to
that of CD43 and CD44 [35], and was equally inhibited by
PMSF in the three antigens, which suggests that proteolysis is a
physiological regulator of neutrophil membrane-associated func-
tions. There is no apparent homology among the three down-
regulated antigens herein studied, CD53, CD43, and CD44.
Thus, either there is a family of proteases, one for each target, or
there is a protease that recognizes a three-dimensional struc-
ture common to apparently unrelated proteins. This putative
protease must already be present in an inactive state in the
resting cell, because its activation takes place immediately
after cell stimulation. The presence of serine protease activity
on cell membranes has long been known, like in the case of
plasminogen activator [37], and in the activation of human
neutrophils [38, 39].
In many cases, the consequence of a protease action is the
release of a soluble form of a growth factor, as is the case for
IL-6, TNF-a, and FasL. In others, there is no solubilization,
just a loss of antigenic reactivity, as is the case with CD43 and
CD44 [35]. This latter process is likely to be occurring in the
case of CD53, as its very hydrophobic nature with four
transmembrane domains makes very unlikely that a proteolytic
cleavage could solubilize the protein, particularly when this
proteolytic attack appears to occur in the loop of the protein
containing the epitope [53]. This is consistent with the lack of
detection of CD53 antigen in soluble form upon cell activation,
and with the reduction of the antigen level that remains
detectable by Western blot on cellular membranes.
Because CD53 antigen is present on the surface of human
neutrophils, which have specific interactions in different
cellular environments, its cell surface expression modulation
might be a mechanism that will allow binding to alternative
molecules. In this context, it could be envisaged that neutro-
phils can detach as a consequence of CD53 down-regulation,
and migrate toward a different location, where the cells could
bind to a, perhaps, distinct ligand molecule. This issue will only
be settled when the specific ligands for CD53 and other
tetra-span transmembrane proteins are identified. This is
important for two major reasons. First, several tetra-span
proteins have been identified as tumor antigens, and their
levels have been correlated with tumor prognosis in several
types of cancer [7–12]. Second, several tetraspanin antigens are
known to be implicated in adhesion processes, such as CD9
[14], CD81 [13], and CD53 [15], and these three antigens interact
with integrins and are modulators of integrin functions [54].
The observations reported in this study further call attention
to the biological importance of selective proteolytic cleavage in
regulation of cell function. The characterization of the specific
proteases involved, as well as the identification of specific
inhibitors, could open up a field of great biological and
pharmacological relevance in the control of specific patholo-
gies. CD53 physiological function remains to be elucidated, but
this antigen is a membrane protein that has been implicated in
signal transduction [21, 55–57]. The proteolytic down-
regulation of CD53, a prototype tetraspanin transmembrane
protein, parallels that of other antigens that are also down-
regulated in neutrophil activation, suggesting that tetraspanin
proteins are a component of the neutrophil cellular interactions
needed for some unknown aspects of their biology and, by
analogy to other neutrophil adhesion proteins, their alteration
might have clinical consequences, like recurrent infections. In
this regard we have recently reported a family with recurrent
infectious diseases that has as the only identified alteration a
deficiency of CD53 antigen [58].
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